Veredus Laboratories’ VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 Receives Provisional Authorisation from the Health Sciences Authority (HSA) in Singapore for In vitro Diagnostic (IVD) Use

Veredus Laboratories Pte Ltd “Veredus” has obtained Provisional Authorisation from Singapore Health Sciences Authority (HSA) for VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 for use as an In vitro Diagnostic (IVD) test in Singapore. Veredus can supply to healthcare institutions, private hospitals, medical clinics and clinical laboratories licensed under the Private Hospitals and Medical Clinics (PHMC) Act in Singapore.

VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 is a one-step Reverse Transcription Polymerase Chain Reaction (RT-PCR)-based IVD test intended for the qualitative detection of nucleic acid belonging to SARS-CoV-2. This test is suitable and easily adaptable for use in qPCR cycler with FAM and HEX (HIC) detection channels.

Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories said, “In response to this COVID-19 pandemic situation, our team worked rapidly to develop an updated with increased sensitivity and user friendliness real-time RT-PCR test to detect SARS-CoV-2. This updated assay provides enhanced tolerance against gene mutations by targeting dual viral N gene targets as well as an inclusion of the human RPP30 gene as the Human Internal Control within the assay. We are proud and excited to receive this Provisional Authorisation IVD from HSA and for Veredus to support laboratories in their diagnostic effort for COVID-19.

Learn more > https://vereduslabs.com/covid-19/